ReviewSkin health and disease2026
Two inflammasomes as tumour markers for nonmelanocytic skin cancer: new hopes for early detection and targeted therapy.
Review in Skin health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonmelanoma skin cancer (NMSC) refers to the most common skin cancers, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Therefore, dependable biomarkers could benefit early predictive diagnosis and become therapy targets. Recent findings have implicated the role of inflammasomes, including (NLRP1 and NLRP3), in skin carcinogenesis. This literature review shall further examine and summarize whether NLRP1 and NLRP3 inflammasomes could be potential tumour markers of NMSC. The literature in this area is synthesized, with the aim of providing a broad understanding of the issue concerning skin cancer. A complete literature search of PubMed, Google Scholar and Web of Science was conducted including publications covering the period January 2000-May 2024. Fifteen relevant articles were included and helped to shed light on the roles of NLRP1 and NLRP3 in NMSC. The included articles comprised original research articles and review papers. In the context of tumour regression and progression, low expression of the NLRP1 inflammasome indicated an increase in metastasis and recurrence in patients with NMSC. Skin cancer is facilitated by a germline mutation in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.